CALT - Calliditas CEO buys 50K shares through warrant exercise

• Calliditas Therapeutics' ( NASDAQ: CALT ) CEO Renée Aguiar-Lucander has acquired 50,000 shares through its warrant program 2019/2022.
• Following the new subscription, Aguiar-Lucander holds 643,000 common shares in the company.
• The majority of the members of management who are eligible option holders in the program have today net purchased shares via the warrant program 2019/2022, which includes 422,500 warrants and can be exercised up to and including December 31, 2022.
• To partially fund the share purchases, the option holders in the program, including the CEO and eligible members of management, have sold shares.
• This sale, which consisted of 352,500 shares, was made in a block transaction.

For further details see: